<DOC>
	<DOCNO>NCT02004041</DOCNO>
	<brief_summary>The purpose study test whether VLY-686 reduce chronic pruritus subject treatment-resistant pruritus associate atopic dermatitis comparison placebo .</brief_summary>
	<brief_title>Proof Concept VLY-686 Subjects With Treatment-Resistant Pruritus Associated With Atopic Dermatitis</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled study conduct two site Germany . Sixty-eight ( 68 ) subject chronic pruritus associate atopic dermatitis , randomize either placebo group active treatment group VLY-686 . The study divide three phase : screening phase , evaluation phase , post-therapy follow-up phase . The screen phase comprises screen visit subject ' preliminary eligibility study evaluate wash-out period subject stop use current topical systemic treatment . The evaluation period comprise 4 week randomize double-blind treatment . The post-therapy follow-up period consist wash-out follow clinic visit safety assessment check residual efficacy treatment .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Pruritus</mesh_term>
	<mesh_term>Neurokinin-1 Receptor Antagonists</mesh_term>
	<criteria>Men woman age 18 65 year , inclusive ; suffer atopic dermatitis SCORAD index inclusion ≤80 ; With atopic lesion arm , leg , trunk neck ; Chronic pruritus pruritus actively present least 6 week prior screen ; Subjects treatmentresistant pruritus ; pruritus duration &gt; 6 week despite use antihistamine corticosteroid ; Pruritus VAS intensity ≥70 mm ( mean intensity one two day precede inclusion study / Baseline Visit ) patient assessment pruritus ( PGA Likert scale item `` pruritus '' ) inclusion ≥3 ; Subjects Body Mass Index ( BMI ) ≥18 ≤35 kg/m2 ( BMI = weight ( kg ) / [ height ( ) ] 2 ) ; Males , nonfecund female , female childbearing potential use 2 independent highly effective barrier method birth control use correctly period 35 day first dose , study one month last dose must negative pregnancy test screen baseline visit ; Vital sign ( 3 minute rest sit semisupine position ) within follow range : Body temperature 35.537.8 °C , Systolic blood pressure 91130 mmHg , Diastolic blood pressure 5190 mmHg , Pulse rate 50100 bpm ; Ability acceptance provide write informed consent ; Willing able comply study requirement restriction include discontinuation current therapy pruritus ; Willing participate clinical trial duration VLY686 trial ; Subjects must good health determine past medical history , physical examination , electrocardiogram , clinical laboratory test urinalysis . Chronic pruritus due condition atopic dermatitis ( AD ) include follow condition : Prurigo nodularis , Lichen simplex chronicus , Bullous pemphigoid ; Other nonAD subject ( notalgia paresthetica , brachioradial pruritus , somatoform prurigo , dilusional parasitosis , depression associate prurigo ) ; Acute superinfection AD ; Current past systematic use topical systemic antihistamine ( 2 week prior Baseline Visit , topical steroid ( 2 week prior Baseline Visit ) , systemic steroid ( 6 week prior Baseline Visit ) , cytotoxic treatment ( 4 week prior Baseline Visit ) , cyclosporin A immunosuppressant ( 8 week prior Baseline Visit ) , naltrexone , paroxetine , fluvoxamine , amitriptyline , gabapentin , pregabalin ( prescribed pruritus treatment , 4 week prior Baseline Visit ) , topical calcineurin inhibitor , topical antibiotic , antiseptic bathe cleanse lotion ( 8 week prior Baseline Visit ) ; Under actual medical treatment skin disease therapy list prohibited medication section may influence result study ; History recent ( within six month ) drug alcohol abuse define DSM V , Diagnostic Criteria Drug Alcohol Abuse evidence abuse indicate laboratory assay conduct Screening Baseline Visits ; Patients currently imminent risk harm self others exclude ; Any major surgery within three month Baseline Visit minor surgery within one month ; Current clinically significant cardiovascular , respiratory , neurologic , hepatic , hematopoietic , renal , gastrointestinal metabolic dysfunction unless currently control stable ; Uncontrolled diabetes mellitus define HbA1c &gt; 7 % fast glucose level &gt; 130 mg/dL ; Positive hepatitis C antibody test ( antiHCV ) ; Positive hepatitis B surface antigen ( HBsAg ) ; History ( include family history ) current evidence congenital long QT syndrome know acquire QT interval prolongation ; Exposure investigational medication , include placebo , within 60 day Baseline Visit ; Exposure ( within 2 week Baseline Visit ) overthecounter medication include melatonin , dietary supplement and/or herbal remedy ; Treatment medication know cause major organ system toxicity ( e.g. , chloramphenicol tamoxifen ) 60 day precede Screening visit ; History intolerance and/or hypersensitivity medication similar VLY686 accompanying excipients ; Participation previous LY686017 VLY686 trial ; Significant illness within two week prior Baseline Visit ; Pregnant lactating female ; Have history cirrhosis laboratory evidence hepatocellular injury , evidence elevated level serum alanine aminotransferase ( ALT ) serum aspartate aminotransferase ( AST ) great 2 time upper limit normal ( 2X ULN ) ; Not willing accept informationtransfer concern participation study , information regard his/her health ( e.g . laboratory result medical history ) ; Anyone affiliate site sponsor and/or anyone may consent duress ; Any sound medical reason determine clinical Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>pruritus</keyword>
	<keyword>atopic dermatitis</keyword>
	<keyword>VLY-686</keyword>
</DOC>